TP53 and neoplasm: Mutant p53 can also activate the MAPK and PI3K/AKT signaling pathways via EGFR/ERBB2, leading to HSF1 activation and HSPs expression, which contribute to tumor progression, chemoresistance, and apoptosis evasion [34] (Figure 1D).